Please assess the completion status of the following clinical trial:

Trial Title: MSB11022 in Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis based on 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria~* At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline~* Must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Evidence of untreated or inadequately treated latent or active Tuberculosis~* Evidence of uncontrolled, clinically significant diseases~* Any second disease-modifying antirheumatic drugs must be washed out prior to the first study dose~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MSB11022 (Type: EXPERIMENTAL): None
- EU-Humira (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).